• Skip to primary navigation
  • Skip to main content
  • Skip to footer

LKT Labs

Biochemicals for Life Science Research

  • Products
    • New Products
    • Cancer Biology
    • Cardiovascular
    • Endocrine Signaling and Immunology
    • Metabolic and GI Pathology
    • Microbiology
    • Natural Products
    • Neuroscience
    • Peptides
    • Pharmaceutical Impurities and Derivatives
    • Stem Cell Modulators
  • Services
    • Custom Synthesis
    • Natural Product Isolation
    • Analytical Services
  • Int’l Distributors
  • Support
    • About LKT Labs
    • General Inquiry
    • Bulk Quote Request
    • Document Request
    • Technical Support
    • Catalog Request
    • Product Flyers
  • Contact Us
  • Cart
  • Login / Register
Afuresertib

Afuresertib

Product ID A225822
Cas No. 1047644-62-1
Purity ≥98%
Product Unit SizeCostQuantityStock
5 mg $122.70 In stock
25 mg $374.90 In stock
100 mg $988.10 In stock
Bulk Quote

Quicklinks

  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Custom Order

Description

Afuresertib is an inhibitor of Akt, a serine/threonine kinase. In addition to showing efficacy in clinical trials as a monotherapy against hematological malignancies, afuresertib has been effective against multiple myeloma. When used in combination with pomalidomide plus dexamethasone, afuresertib exhibited antitumor activity in multiple myeloma cells. It has also shown efficacy in patients with malignant pleural mesothelioma.

Product Info

Cas No.

1047644-62-1

Purity

≥98%

Formula

C18H17Cl2FN4OS

Formula Wt.

427.32

IUPAC Name

N-[(2S)-1-Amino-3-(3-fluorophenyl)-2-propanyl]-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-thiophenecarboxamide

Synonym

GSK-2110183C, GSK-2110183

Shipping and Storage

Store Temp

-20°C

Ship Temp

Ambient

Downloads

MSDS

A225822 MSDS PDF

Info Sheet

A225822 Info Sheet PDF

References

Kinoshita S., Ri M., et al. Potent antitumor effect of combination therapy with sub-optimal doses of Akt inhibitors and pomalidomide plus dexamethasone in multiple myeloma. Oncol Lett. 15(6):9450-56 (2018). PMID: 29927335.

Yamaji M., Ota A., et al. Novel ATP-competitive Akt inhibitor afuresertib suppresses the proliferation of malignant pleural mesothelioma cells. Cancer Med. 6(11):2646-59 (2017). PMID: 28960945.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Related Products

  • R3205

    Ribavirin

    Purine nucleoside analog; DNA chain terminator....

    ≥98%
  • S801001

    SU-5402

    Inhibitor of VEGFR and FGFR.

    ≥98%
  • E4417

    Eledoisin Related Peptide

    Peptide, substance P analog; NK agonist.

    ≥95%
  • D1859

    2-Deoxy-D-glucose

    Glucose metabolism inhibitor, N-linked glycosyl...

    ≥99%
  • V1769

    Verapamil Hydrochloride

    L-type Ca2+ channel blocker.

    ≥98%
  • B1996

    BEZ235

    PI3K and mTOR inhibitor.

    ≥98%
  • L8248

    Lumiracoxib

    NSAID; COX-2 inhibitor.

    ≥98%
  • N8660

    NVP-AUY922

    Isoxazole derivative; HSP90 inhibitor.

    ≥98%
  • G1210

    GDC-0623

    MEK inhibitor.

    ≥98%
  • K2412

    KGDS

    Synthetic peptide, fibrinogen derivative; glyco...

    ≥95%
  • S0269

    SAR245409

    Pyridopyrimidinone; PI3K and mTOR inhibitor.

    ≥96%
  • E499601

    Empagliflozin

    SGLT2 inhibitor

    ≥98%
  • C2900

    CH5424802

    ALK inhibitor.

    ≥99%
  • A5275

    [Des-Asp1]-Angiotensin I, human

    Peptide, derivative of AT I, cleavage product o...

    ≥95%
  • V1600

    VE-821

    ATR inhibitor.

    ≥98%
  • N0061

    D-Naproxen

    NSAID; COX-1/2 inhibitor.

    ≥99%
  • X4400

    XL-228

    Abl (T315I) inhibitor.

    ≥98%
  • T7860

    TTP 22

    Casein kinase 2 inhibitor.

    ≥98%
  • L0360

    Lapatinib Ditosylate Monohydrate

    EGFR inhibitor.

    ≥99%
  • M1777

    R-(−)-α-Methylbenzyl Isothiocyanate

    ITC, used as chiral agent.

    ≥98%

Footer

  • Contact Us
  • About Us
  • Site Map
  • Terms and Conditions
LKT Laboratories, Inc.
545 Phalen Blvd.
St. Paul MN, 55130

Ph: (888)-558-5227
Fax: (888)-558-7329

©2025 LKT Laboratories, All Rights Reserved - Products for research use only